To address this issue, various strategies have been developed to create next-generation anti-CD137 agonists that target the agonistic activity more specifically to the tumor site while limiting the agonistic activity in normal tissues to reduce immune-toxicity (30). The gene discussed is TNFRSF9; the disease is neoplasm.